Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the de...
HC Wainwright & Co. analyst Ed Arce reiterates Paratek Pharmaceuticals (NASDAQ:PRTK) with a Neutral and maintains $2.15 ...
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of...
HC Wainwright & Co. analyst Ed Arce reiterates Paratek Pharmaceuticals (NASDAQ:PRTK) with a Neutral and maintains $2.15 ...
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones -- ...
Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the d...
